Marra Alessandro, Hillejan Ludger, Zaboura George, Fujimoto Toshio, Greschuchna Dieter, Stamatis Georgios
Department of Thoracic Surgery and Endoscopy, Ruhrlandklinik, Essen, Germany.
J Thorac Cardiovasc Surg. 2003 Mar;125(3):543-53. doi: 10.1067/mtc.2003.322.
Patients with N1 non-small cell lung cancer represent a heterogeneous population with varying long-term survivals. Prognosis and pattern of recurrence seem to be particularly affected by the level of lymph node involvement.
From 1990 to 1995, a total of 1954 consecutive patients underwent surgical resection for non-small cell lung cancer: 549 (28%) had ipsilateral pulmonary lymph node metastases (N1). The hospital survivors (n = 535) were reviewed. Three levels of lymph node metastases (hilar, interlobar, and lobar) were identified according to the new Regional Lymph Node Classification for Lung Cancer Staging and differentiated from lymph node involvement on the basis of direct invasion.
1 The overall 5-year survival of patients with N1 disease was 40%. Survival was related in the univariate analysis to T classification, level-type of N1 involvement, number of involved nodes, multilevel involvement, Karnofsky Index, R status, and adjuvant therapy. In the multivariate analysis, only T classification and level-type of N1 involvement clearly showed statistical power (P =.000 and P =.001, respectively). The pattern of cancer relapse according to level-type of N1 involvement differed significantly: hilar N1 disease recurred at distant sites in 41% of patients and locoregionally in 12% of patients, whereas N1 disease by direct invasion occurred in 24% and 17% of patients, respectively (P =.030).
Metastases to ipsilateral hilar, interlobar, or both, lymph nodes are associated with a poorer prognosis compared with metastases in intralobar lymph nodes or with lymph node involvement by means of direct invasion. Although surgical resection remains the mainstay of treatment, the high rate of tumor recurrence in both groups mandates further randomized studies with multimodality therapy approaches.
N1期非小细胞肺癌患者是一个异质性群体,长期生存率各不相同。预后和复发模式似乎特别受淋巴结受累程度的影响。
1990年至1995年,共有1954例连续的患者接受了非小细胞肺癌的手术切除:549例(28%)有同侧肺门淋巴结转移(N1)。对医院幸存者(n = 535)进行了回顾。根据肺癌分期的新区域淋巴结分类确定了三级淋巴结转移(肺门、叶间和叶内),并与基于直接侵犯的淋巴结受累情况相区分。
与叶内淋巴结转移或通过直接侵犯导致的淋巴结受累相比,同侧肺门、叶间或两者的淋巴结转移与较差的预后相关。尽管手术切除仍然是主要的治疗方法,但两组中肿瘤复发率都很高,这就要求进一步开展多模式治疗方法的随机研究。